Effectiveness of recombinant human follicle-stimulating hormone (r-hFSH): recombinant human luteinizing hormone versus r-hFSH alone in assisted reproductive technology treatment cycles among women aged 35-40 years: A German database study

A P Bielfeld, Bielfeld AP, J E Schwarze, Schwarze JE, Verpillat P, P. Verpillat, Lispi M, M Lispi, Fischer R, R Fischer, Hayward B, B Hayward, D Chuderland, Chuderland D, T. D'Hooghe, D'Hooghe T, J S Krussel, Krussel JS
Best practice & research. Clinical obstetrics & gynaecology · 2023 · vol. 89 , pp. 102350 · doi:10.1016/j.bpobgyn.2023.102350 · PMID:37320996
review OA: hybrid CC-BY-4.0
🔓 Open OA copy View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

This study found that recombinant human FSH with recombinant human LH resulted in numerically higher pregnancy and live birth rates compared to recombinant human FSH alone in women aged 35-40 undergoing assisted reproduction.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

This non-interventional study compared the effectiveness of recombinant human follicle-stimulating hormone (r-hFSH) and recombinant human luteinizing hormone (r-hLH) (2:1 ratio) versus r-hFSH alone for ovarian stimulation (OS) during assisted reproductive technology treatment in women aged 35-40 years, using real-world data from the Deutsches IVF-Register (D·I·R). Numerically higher clinical pregnancy (29.8% [95% CI 28.2, 31.6] vs. 27.8% [26.5, 29.2]) and live birth (20.3% [18.7, 21.8] vs. 18.0% [16.6, 19.4]) rates were observed with r-hFSH:r-hLH versus r-hFSH alone. The treatment effect was consistently higher for r-hFSH:r-hLH compared with r-hFSH alone in terms of clinical pregnancy (relative risk [RR] 1.16 [1.05, 1.26]) and live birth (RR 1.16 [1.02, 1.31]) in a post-hoc analysis of women with 5-14 oocytes retrieved (used as a surrogate for normal ovarian reserve), highlighting the potential benefits of r-hFSH:r-hLH for OS in women aged 35-40 years with normal ovarian reserve.

My notes (saved in your browser only)

MeSH descriptors

Follicle Stimulating Hormone, Human Follicle Stimulating Hormone, Human Follicle Stimulating Hormone, Human Follicle Stimulating Hormone, Human Follicle Stimulating Hormone, Human Follicle Stimulating Hormone, Human Follicle Stimulating Hormone, Human Follicle Stimulating Hormone, Human Follicle Stimulating Hormone, Human Follicle Stimulating Hormone, Human Follicle Stimulating Hormone, Human Follicle Stimulating Hormone, Human Follicle Stimulating Hormone, Human Follicle Stimulating Hormone, Human Follicle Stimulating Hormone, Human Follicle Stimulating Hormone, Human Follicle Stimulating Hormone, Human Follicle Stimulating Hormone, Human Follicle Stimulating Hormone, Human Follicle Stimulating Hormone, Human

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-09-13T09:25:22.628771+00:00
pubmed
last seen: 2026-09-18T06:09:44.632648+00:00
unpaywall
last seen: 2026-05-15T02:00:00.661756+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine